Canine Pipeline

Atopic Dermatitis in Dogs


IL31 Antibody
IL17 Antibody
IL4/13 SINK
IL4R Antibody

POSITIVE RESULTS FROM PILOT FIELD EFFECTIVENESS STUDY OF KIND-016

We plan to begin a pivotal study on IL 31 by year-end 2020

“Itch associated with Atopic Dermatitis may be caused by either neurogenic, inflammatory and/or behavioral pathomechanisms. I often find that I need to address a combination of pathways to successfully control itch in my atopic patients.”

- Tony Yu, BSc, DVM, MS ACVD

KindredBio is pursuing a multi-pronged approach toward atopic dermatitis, with a portfolio of promising biologics.

KindredBio reported positive topline results from its pilot field effectiveness study of KIND-016, a fully caninized, high-affinity monoclonal antibody targeting interleukin-31, for the treatment of atopic dermatitis in dogs.

The company also expects pilot effectiveness results for its canine anti-IL-4/IL-13 SINK molecule by the first quarter of 2020 and is advancing other programs for atopic dermatitis.

Prevalence

Itch is #1 reason for canine veterinarian visits

Diagnosis

10-15%

have atopic dermatitis, an allergic skin disease

Key Profit Center

83%

of dogs seen by dermatologists suffer from from pruritis (itch)

Growing Market

47%

increase in itchy dog veterinarian vists since 2014

Current market size is $600M annually and growing.

Learn More About:

KindredBio Investor Relations Atopic Dermatitis in Dogs

US-CORP-1900168 FEB-20

Canine Pipeline

Atopic Dermatitis in Dogs

News

Events